Details for Patent: 11,998,529
✉ Email this page to a colleague
Which drugs does patent 11,998,529 protect, and when does it expire?
Patent 11,998,529 protects IGALMI and is included in one NDA.
This patent has eleven patent family members in eleven countries.
Drugs Protected by US Patent 11,998,529
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioxcel | IGALMI | dexmedetomidine hydrochloride | FILM;BUCCAL, SUBLINGUAL | 215390-001 | Apr 5, 2022 | RX | Yes | Yes | 11,998,529 | ⤷ Subscribe | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION | ⤷ Subscribe | ||||
| Bioxcel | IGALMI | dexmedetomidine hydrochloride | FILM;BUCCAL, SUBLINGUAL | 215390-002 | Apr 5, 2022 | RX | Yes | Yes | 11,998,529 | ⤷ Subscribe | ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,998,529
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020316013 | ⤷ Subscribe | |||
| Brazil | 112022000992 | ⤷ Subscribe | |||
| Canada | 3145388 | ⤷ Subscribe | |||
| China | 114375191 | ⤷ Subscribe | |||
| European Patent Office | 3999058 | ⤷ Subscribe | |||
| Israel | 289735 | ⤷ Subscribe | |||
| Japan | 2022540706 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
